secwatch.observer — SEC 8-K summary
======================================

Issuer:     Enliven Therapeutics, Inc. (ELVN)
CIK:        0001672619
Form:       8-K
Filed at:   2024-08-13T23:59:59+00:00
Accession:  0000950170-24-096204
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Enliven Therapeutics Q2 net loss $20.0M; cash $312.4M; pipeline advances with ELVN-001/002 dosing starts
--------------------------------------------------------------------------------

- Cash, cash equivalents and marketable securities of $312.4M as of June 30, 2024, expected to fund operations into late 2026.
- Q2 2024 net loss $20.0M ($16.7M Q2 2023); R&D expense $18.8M ($15.2M), G&A $5.8M ($5.0M).
- ELVN-001 Phase 1b arm dosing initiated in CML patients; abstract accepted for September ESH-iCMLf conference.
- ELVN-002 Phase 1a combo trial with trastuzumab +/- chemo and exploratory arm with Kadcyla dosed first patients.
- Phase 1 data for ELVN-001 and initial ELVN-002 combo data expected in 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1672619/000095017024096204/0000950170-24-096204-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1672619/000095017024096204/elvn-20240813.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-096204

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer